Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

9.51USD
18 Apr 2018
Change (% chg)

$0.03 (+0.32%)
Prev Close
$9.48
Open
$9.49
Day's High
$9.55
Day's Low
$9.49
Volume
7,530
Avg. Vol
12,048
52-wk High
$15.75
52-wk Low
$5.48

Chart for

About

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein... (more)

Overall

Beta: --
Market Cap(Mil.): $70.42
Shares Outstanding(Mil.): 9.71
Dividend: --
Yield (%): --

Financials

  KALV.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -3.21 -- --
ROI: -60.80 14.84 14.38
ROE: -61.05 16.34 16.07

BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials

* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001

05 Jan 2018

BRIEF-Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50

* KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS

14 Dec 2017

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

14 Nov 2017

BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​

* Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​ Source text - http://bit.ly/2xTHJJO Further company coverage:

21 Oct 2017

Earnings vs. Estimates